Meet Bille, the name given to the world's first monostable tetrahedron—a four-faced object that will always land on the same ...

Furthermore, diabetes mellitus is intricately linked to pancreatic carcinoma, with diabetes-associated cancers presenting distinct molecular signatures ... researchers across different fields and ...

Molecular machine learning (ML) underpins critical workflows in drug discovery, material science, and catalyst optimization by rapidly predicting molecular interactions and properties. For ...

Adoption of lecanemab, a novel infusion treatment for Alzheimer's disease (AD), ... Study reveals how Alzheimer's disease and attention shape our ability to remember. Jun 25, 2025.

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, “real-world” data from people with mild Alzheimer's disease shows.

Treatment with lecanemab infusion was safe and generally well-tolerated within an outpatient memory clinic setting, with few infusion-related reactions and a low number of withdrawals due to ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) ...

04/15/2025 April 15, 2025. The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

Lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early AD) who are apolipoprotein E ε4 (ApoE ε4 *) ...

Recent Alzheimer's research has led to FDA-approved treatments that slow cognitive decline, such as Lecanemab and Donanemab. New diagnostic tools like PET scans and blood biomarker tests allow for ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisation approval decision of lecanemab in ...